# LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)

> **NCT04031872** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **The Netherlands Cancer Institute**

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** LY3200882

## Key facts

- **NCT ID:** NCT04031872
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-01-01
- **Primary completion:** 2020-01-01
- **Final completion:** 2020-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No IMP available and Covid
- **Last updated:** 2025-09-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04031872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04031872, "LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04031872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*